A Phase II Trial of TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Carcinoma of the Lung

Trial Profile

A Phase II Trial of TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Carcinoma of the Lung

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2017

At a glance

  • Drugs Tipiracil/trifluridine (Primary)
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jun 2017 Planned End Date changed from 30 Jun 2021 to 30 Jul 2021.
    • 30 Jun 2017 Planned primary completion date changed from 30 Jun 2020 to 30 Jul 2020.
    • 30 May 2017 Planned End Date changed from 31 May 2021 to 30 Jun 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top